RESI San Diego – Early Bird Rate Ends Tomorrow

20 Apr

By Lucy Parkinson, Director of Research, LSN

For the first time, the Redefining Early Stage Investments (RESI) Conference is coming to San Diego, CA. On Monday June 19th, of Bio week, RESI will provide an opportunity to start your week at the Westin San Diego Gaslamp Quarter with up to 16 face to face meetings with the most relevant global investors for your technology. Not only that, but 3 full-day program tracks of investor panels and workshops will help scientist-entrepreneurs learn the ins and outs of early stage fundraising issues.

RESI’s early bird rate ends tomorrow.  If you are headed to BIO and want to achieve maximum ROI on your trip to San Diego, get your RESI pass today.

 

RESI San Diego Agenda Announcement

20 Apr

By Michael Quigley, VP of Market Research, LSN

mike-2

For its first trip to San Diego, the Redefining Early Stage Investments (RESI) conference team will be bringing with it a content rich agenda. RESI’s Biotech and Medtech tracks will feature over 75 investor speakers across 16 panels devoted to specific investor types, technology sectors, or new issues in fundraising. Representatives from family offices, big pharma, VC, angels and more will share with the audience the types of opportunities they are currently looking for as well as what it is like to be on the other side of the negotiating table.

RESI’s Early Stage Workshops track features 4 entrepreneur education workshops, including a new session on 505(b)(2) Strategy led by Ken Phelps, CEO of Camargo.

With our Asia-North America Track, one of our newer and most popular additions, attendees will get the chance to hear directly from investors and strategic partners from across the Pacific looking for North American innovation. These panels will be a must-see for any fundraising entrepreneur in the sector.

We are very excited to bring this diverse pool of investors and speakers to San Diego to share their expertise and experience with the hundreds of fundraising scientist-entrepreneurs who attend RESI. While many of our speaking spots are already allocated, if you or someone you know would want to participate please don’t hesitate to reach out.

Get Your Startup in the Spotlight at the RESI Innovation Challenge in San Diego

20 Apr

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

RESI is going to BIO. As we join 2017’s largest life science innovation carnival, we aim to showcase the most promising, innovative new health technologies in the RESI Innovation Challenge. If you’re headed to San Diego with the aim of raising money or making deals for your startup, we’d like to see your application.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On June 19th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder, Steadiwear | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

RESI on MaRS 2017 Innovation Challenge 1st Place Winner – Steadiwear inc.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

APPLICATION DEADLINE: May 5, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 

– Raymond Shih, President, Co-Founder, QoC Health

3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

Hot Investor Mandate 1: Family Office Invests in Growth Stage Healthtech and Health Service Companies

20 Apr

A family office located in New York makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Canadian Venture Capital Focuses on Software-Enabled Devices, Wearables and Hospital Efficiency

20 Apr

A Toronto-based venture capital firm seeks to make 4-5 new investments per year, and typically co-invests in seed, venture and series A investments at $200,000 – $1M per company. The firm has partnerships with medical software/device, fintech and ICT funds in which the firm will pass on deal flow. The firm has particular preference to companies located in North America, though is open to Australia and Western Europe depending on the opportunity, and does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology and software-enabled technology, particularly ones that can improve hospital operations. The firm does not have a preference for any specific indication areas. The firm does not have revenue requirements for wearable technology and is not particularly interested in products that require regulatory pathways. The firm is interested in companies that are in the development or clinical-stage but will only invest in healthcare IT companies if it is already established with positive cash flow. Outside of software and wearable technology, the firm will look at medical devices to evaluate and connect to partnered funds.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Pharma Firm Seeks Novel Drugs in Blood Cancers, Pediatric Diseases and Sleep Disorders

20 Apr

A pharma firm headquartered in Europe, with offices in the U.S. and across Europe, forms in-licensing relationships and partnerships with development-stage pharmaceutical companies. The firm is open to partnering with companies globally.

The firm is focused on hematology-oncology, and sleep disorders. The firm is also interested in reviewing assets in pediatric oncology, niche areas of CNS and other rare disorders, particularly pediatric diseases. The firm generally prefers that assets that have obtained proof of concept in humans, but may look at earlier stage opportunities in the firm’s key areas of hematology-oncology or sleep disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Pan-European Venture Firm Invests in Medtech, Digital Health and Life Science Tools

20 Apr

A venture firm with offices in Germany and in Eastern Europe has over €850 million in total assets under management, and has raised a total of six funds; the most recent fund closed in 2016. The firm typically invests €1-5 million in venture-stage opportunities, or up to €15 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.

Within the life science sector the firm is currently focused on medical technology, diagnostics, life science tools, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.

The firm is open to investing in companies at the early commercialization stage, and companies generating steady revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com